Anlotinib Combined with TQB2450 in Patients with Platinum-Resistant or -Refractory Ovarian Cancer: A Multi-Center, Single-Arm, Phase 1b Trial
Cell reports Medicine（2022）
关键词
ovarian cancer,platinum-resistant,immunotherapy,immune checkpoint inhibitor,PD-1 inhibitor,PD-L1 inhibitor,targeted therapy,VEGFR inhibitor,anlotinib,TQB2450
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要